GeneDx Holdings Corp. (WGS) stock
WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$51.02−1.35 (-2.58%)
Close on Nov 16, 2026Market cap $1.52BP/E –Yield –
GeneDx EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
GeneDx's EPS for the twelve months ending Jun 30, 2026 was -$3.64, down 18300.0% year over year. For fiscal 2025 it was -$0.73. The highest annual figure on record is -$0.73 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.73 | – |
| FY2024 | Dec 31, 2024 | -$1.94 | – |
| FY2023 | Dec 31, 2023 | -$7.23 | – |
| FY2022 | Dec 31, 2022 | -$53.63 | – |
| FY2021 | Dec 31, 2021 | -$74.91 | – |
| FY2020 | Dec 31, 2020 | -$1552188.00 | – |
| FY2019 | Dec 31, 2019 | -$8713848.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.60 | -266.7% |
| Q1 FY2026 | Mar 31, 2026 | -$2.16 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.61 | -405.0% |
| Q3 FY2025 | Sep 30, 2025 | -$0.27 | – |
| Q2 FY2025 | Jun 30, 2025 | $0.36 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.23 | – |
| Q4 FY2024 | Dec 31, 2024 | $0.20 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.31 | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.10 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.78 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.99 | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.64 | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.84 | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.04 | – |
| Q4 FY2022 | Dec 31, 2022 | -$26.34 | -598.9% |
| Q3 FY2022 | Sep 30, 2022 | -$6.72 | – |
| Q2 FY2022 | Jun 30, 2022 | -$8.38 | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.38 | – |
| Q3 FY2021 | Sep 30, 2021 | $5.28 | – |
| Q2 FY2021 | Jun 30, 2021 | -$1384.02 | – |
| Q1 FY2021 | Mar 31, 2021 | -$11511.06 | – |
| Q3 FY2020 | Sep 30, 2020 | -$15066909.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?